Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review

J Am Coll Cardiol. 2024 Jan 2;83(1):82-108. doi: 10.1016/j.jacc.2023.09.831.

Abstract

Electrophysiological and interventional procedures have been increasingly used to reduce morbidity and mortality in patients experiencing cardiovascular diseases. Although antithrombotic therapies are critical to reduce the risk of stroke or other thromboembolic events, they can nonetheless increase the bleeding hazard. This is even more true in an aging population undergoing cardiac procedures in which the combination of oral anticoagulants and antiplatelet therapies would further increase the hemorrhagic risk. Hence, the timing, dose, and combination of antithrombotic therapies should be carefully chosen in each case. However, the maze of society guidelines and consensus documents published so far have progressively led to a hazier scenario in this setting. Aim of this review is to provide-in a single document-a quick, evidenced-based practical summary of the antithrombotic approaches used in different cardiac electrophysiology and interventional procedures to guide the busy clinician and the cardiac proceduralist in their everyday practice.

Keywords: atrial fibrillation; cardiac pacing; cardioversion; catheter ablation; direct oral anticoagulants; left atrial appendage closure; mitral valve replacement; percutaneous coronary interventions; transaortic valve replacement; ventricular tachycardia.

Publication types

  • Review

MeSH terms

  • Aged
  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / drug therapy
  • Fibrinolytic Agents / adverse effects
  • Hemorrhage / chemically induced
  • Humans
  • Stroke* / drug therapy
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Anticoagulants